Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Aytu is committed to better health for men and women here at home and worldwide. W...
Aytu is committed to better health for men and ...
Amorepacific is Koreaâs No.1 beauty company and a blue-chip corporation. Amorepa...
Amorepacific is Koreaâs No.1 beauty company a...
RadNet is the national leader in outpatient imaging. Backed by 30 years of experie...
RadNet is the national leader in outpatient ima...
Coherus BioSciences is a leading biosimilar company that develops and commercializ...
Coherus BioSciences is a leading biosimilar com...
CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immun...
CytoSorbents Corporation (NASDAQ: CTSO) is a Ne...
Terumo Corporation is a manufacturer and supplier of pharmaceuticals and medical t...
Terumo Corporation is a manufacturer and suppli...
We are a global frontrunner in making oral vaccines a reality. Weâve created a p...
We are a global frontrunner in making oral vacc...
Join the National Investor Network and get the latest information with your interests in mind.